www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-definanzen.net GmbHhttp://images.finanzen.net/images/finanzen_net_neu.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-Announces-Expiration-of-the-Hart-Scott-Rodino-Waiting-Period-for-Merger-with-Galderma-Pharma-S-A-303909CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired in connection with the pending merger of CollaGenex with ...http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-Announces-Expiration-of-the-Hart-Scott-Rodino-Waiting-Period-for-Merger-with-Galderma-Pharma-S-A-303909http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-Reports-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2007-300466CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today reported financial results for the fourth quarter and year ended December 31, 2007. Net revenues were $17.0 million in the fourth quarter of 2007 compared to net revenues of ...http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-Reports-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2007-300466http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2007-Financial-Results-Conference-Call-on-March-12th-297259CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that it will hold a conference call on Wednesday, March 12, 2008, at 11:00 a.m. Eastern Time to discuss the Company's fourth quarter and full year 2007 financial results. ...http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2007-Financial-Results-Conference-Call-on-March-12th-297259http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-Signs-Merger-Agreement-with-Galderma-Pharma-S-A-292742CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that it has entered into a definitive merger agreement with an affiliate of Galderma Pharma S.A., pursuant to which Galderma’s U.S. holding company, Galderma Laboratories, ...http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-Signs-Merger-Agreement-with-Galderma-Pharma-S-A-292742http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-to-Present-at-Roth-Capital-Partners-20th-Annual-OC-Growth-Stock-Conference-on-February-20th-288130CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that Colin W. Stewart, president and chief executive officer, will present at Roth Capital Partners’ 20th Annual OC Growth Stock Conference. The presentation is scheduled ...http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-to-Present-at-Roth-Capital-Partners-20th-Annual-OC-Growth-Stock-Conference-on-February-20th-288130http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-to-Present-at-the-2008-Wachovia-Healthcare-Conference-on-January-30th-277672CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that Colin W. Stewart, president and chief executive officer, will present at the 2008 Wachovia Healthcare Conference. The presentation is scheduled for 8:00 a.m. EST ...http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-to-Present-at-the-2008-Wachovia-Healthcare-Conference-on-January-30th-277672http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-Announces-Results-of-Phase-4-Clinical-Study-Showing-Oracea-Equally-Effective-as-100-mg-Doxycycline-in-Treatment-of-Rosacea-275336CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced results of a Phase 4 dose-comparison study designed to evaluate the safety and efficacy of Oracea(R) once daily versus doxycycline 100 mg once daily for the treatment ...http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-Announces-Results-of-Phase-4-Clinical-Study-Showing-Oracea-Equally-Effective-as-100-mg-Doxycycline-in-Treatment-of-Rosacea-275336http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-Initiates-Phase-2-Dose-Finding-Study-of-Becocalcidiol-for-the-Treatment-of-Psoriasis-273406CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced that it has initiated a Phase 2, double-blinded, placebo- and active-controlled, dose-finding clinical trial to evaluate the safety and efficacy of its novel compound, ...http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-Initiates-Phase-2-Dose-Finding-Study-of-Becocalcidiol-for-the-Treatment-of-Psoriasis-273406http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-to-Present-at-the-RBC-Capital-Markets-Healthcare-Conference-on-December-12th-260639CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that Colin W. Stewart, president and chief executive officer, will participate on a panel at the RBC Capital Markets’ Healthcare Conference. The "Finding Beauty in ...http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-to-Present-at-the-RBC-Capital-Markets-Healthcare-Conference-on-December-12th-260639http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-to-Present-at-the-BMO-Capital-Markets-Focus-on-Healthcare-Conference-on-December-4th-256625CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that Colin W. Stewart, president and chief executive officer, will present at the BMO Capital Markets Focus on Healthcare Conference. The presentation is scheduled for ...http://www.finanzen.net/nachricht/aktien/CollaGenex-Pharmaceuticals-to-Present-at-the-BMO-Capital-Markets-Focus-on-Healthcare-Conference-on-December-4th-256625